Inhalation Sciences signs exclusive distribution agreement with Sanyo Trading, Japan

Report this content

(Stockholm, Sweden, May 25, 2021) The agreement grants Sanyo Trading exclusive sales rights to ISAB instruments in Japan, with a minimum purchasing commitment of 3 000 000 SEK in 2021 and a minimum of 5 000 000 SEK in 2022.

ISAB has significantly strengthened its global sales strategy recently, with increased activities in the US and the signing of a new distribution agreement covering India, Bangladesh and Sri Lanka. Japan is a key target market for ISAB, with a large population, a robust research sector, advanced technology and strong pricing levels.

Founded in 1947, Sanyo Trading is one of the country’s most prestigious traders in scientific equipment, with 2019 revenues of 770 MUSD. Sanyo Trading is the exclusive distributor of Copley Instruments in Japan – giving the company strong ties and an exceptional reputation and network in the country’s inhalation research community. Copley Instruments is a non-competing product line that includes tools which can be complementary to Inhalation Sciences' instruments.

ISAB COO Paolo Raffaelli: “We’re honored to sign this agreement with such a prestigious and able partner. Sanyo Trading’s expertise, heritage and outstanding reputation is a powerful strategic benefit in this important and dynamic market.”

CEO Manoush Masarrat: “Our new agreement with Sanyo Trading reflects the enormous global sales potential for our instruments – and the solid work we’re doing in putting concrete goals and targets in place. This is sure to be a fruitful relationship for both of our companies.”

For more information about Inhalation Sciences, please contact:

Manoush Masarrat, CEO


Mobile: +46 (0)73 628 9153

About Inhalations Sciences Sweden AB (publ)

Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments and services for research into inhalation. The company’s patented lab instruments PreciseInhale® and DissolvIt® enable researchers in the pharma industry to make drug pipeline decisions at an early stage, saving time and resources for R&D departments, and enables researchers in academic institutions to define how aerosols and small particles impact our lungs, and so our health, when being inhaled.